These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

399 related items for PubMed ID: 25819278

  • 21. Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy.
    Zhong Y, Meng F, Deng C, Zhong Z.
    Biomacromolecules; 2014 Jun 09; 15(6):1955-69. PubMed ID: 24798476
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Using nanotechnology to improve the characteristics of antineoplastic drugs: improved characteristics of nab-paclitaxel compared with solvent-based paclitaxel.
    Foote M.
    Biotechnol Annu Rev; 2007 Jun 09; 13():345-57. PubMed ID: 17875482
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Reinvention of chemotherapy: drug conjugates and nanoparticles.
    Nguyen-Ngoc T, Raymond E.
    Curr Opin Oncol; 2015 May 09; 27(3):232-42. PubMed ID: 25783982
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting.
    Huynh NT, Roger E, Lautram N, Benoît JP, Passirani C.
    Nanomedicine (Lond); 2010 Nov 09; 5(9):1415-33. PubMed ID: 21128723
    [Abstract] [Full Text] [Related]

  • 33. Transferrin-Conjugated Nanocarriers as Active-Targeted Drug Delivery Platforms for Cancer Therapy.
    Nogueira-Librelotto DR, Codevilla CF, Farooqi A, Rolim CM.
    Curr Pharm Des; 2017 Nov 09; 23(3):454-466. PubMed ID: 27784246
    [Abstract] [Full Text] [Related]

  • 34. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK, Singh A, Ganta S, Amiji MM.
    Adv Drug Deliv Rev; 2013 Nov 09; 65(13-14):1784-802. PubMed ID: 23880506
    [Abstract] [Full Text] [Related]

  • 35. Albumin-based nanoparticles as potential controlled release drug delivery systems.
    Elzoghby AO, Samy WM, Elgindy NA.
    J Control Release; 2012 Jan 30; 157(2):168-82. PubMed ID: 21839127
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Preclinical investigation of nanoparticle albumin-bound paclitaxel as a potential treatment for adrenocortical cancer.
    Demeure MJ, Stephan E, Sinari S, Mount D, Gately S, Gonzales P, Hostetter G, Komorowski R, Kiefer J, Grant CS, Han H, Von Hoff DD, Bussey KJ.
    Ann Surg; 2012 Jan 30; 255(1):140-6. PubMed ID: 22156929
    [Abstract] [Full Text] [Related]

  • 38. Enhanced drug-loading and therapeutic efficacy of hydrotropic oligomer-conjugated glycol chitosan nanoparticles for tumor-targeted paclitaxel delivery.
    Koo H, Min KH, Lee SC, Park JH, Park K, Jeong SY, Choi K, Kwon IC, Kim K.
    J Control Release; 2013 Dec 28; 172(3):823-31. PubMed ID: 24035978
    [Abstract] [Full Text] [Related]

  • 39. Dual-peptide-functionalized albumin-based nanoparticles with ph-dependent self-assembly behavior for drug delivery.
    Chen B, He XY, Yi XQ, Zhuo RX, Cheng SX.
    ACS Appl Mater Interfaces; 2015 Jul 22; 7(28):15148-53. PubMed ID: 26168166
    [Abstract] [Full Text] [Related]

  • 40. Antibody conjugated PLGA nanoparticles for targeted delivery of paclitaxel palmitate: efficacy and biofate in a lung cancer mouse model.
    Karra N, Nassar T, Ripin AN, Schwob O, Borlak J, Benita S.
    Small; 2013 Dec 20; 9(24):4221-36. PubMed ID: 23873835
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.